Gal9/Tim-3 expression level is higher in AML patients who fail chemotherapy

Abstract Immune checkpoint pathways active in Acute Myeloid Leukemia (AML) patients, especially during the course of remission induction chemotherapy, have not been well studied. Although dominant in mediating T cell dysfunction in cancer, it is now well-accepted that interruption of PD-1/PD-L1 axes...

Full description

Bibliographic Details
Main Authors: Paola Dama, Marshall Tang, Noreen Fulton, Justin Kline, Hongtao Liu
Format: Article
Language:English
Published: BMJ Publishing Group 2019-07-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Online Access:http://link.springer.com/article/10.1186/s40425-019-0611-3